10-QHealthcare

Edwards Lifesciences Corporation

EW · Period ending 2026-09-30 · Filed 2026-11-04 · Updated

In short

Edwards Lifesciences Corporation (EW) has revenue up 11.5% to $6.1B and net income down 74.3% to $1.1B year on year. Its net margin is 17.7% and gross margin 78.0%, and it trades at 59.1× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$101.85

P/E (TTM)

59.2x

Price ÷ earnings per share

P/B

5.4x

Price ÷ book value

P/S (TTM)

8.8x

Price ÷ revenue per share

Beta

0.83

Moderate market correlation

PEG Ratio

2.2x

P/E ÷ earnings growth rate

52-Week Range

$74.66$101.85 now$108.00

Decision Context

Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

EW vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.2%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — EW

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Operating Cash Flow: $1.6B (+194.2% YoY) — Operating cash flow grew 194% — the business generated more cash from day-to-day operations.

  • Revenue: $6.1B (+11.5% YoY) — Revenue grew 12% — the company sold more goods or services than the prior year.

  • Gross Profit: $4.7B (+9.5% YoY) — Gross profit rose 10% — the spread between revenue and direct costs improved.

◈

Weaknesses

  • Net Income: $1.1B (-74.3% YoY) — Profit fell 74% but remained positive.

  • EPS (Diluted): $1.83 (-73.7% YoY) — Earnings per share fell 74%.

  • Stock is near its 52-week high (100.25) — the price reflects strong recent momentum, but entry risk is elevated at these levels.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Net income dropped 74% year-over-year — a significant compression in profitability.

Year-over-Year Changes

Operating Cash Flow

$1.6B

was $542.3M

+194.2%

Operating cash flow grew 194% — the business generated more cash from day-to-day operations.

Net Income

$1.1B

was $4.2B

−74.3%

Profit fell 74% but remained positive.

EPS (Diluted)

$1.83

was $6.97

−73.7%

Earnings per share fell 74%.

Revenue

$6.1B

was $5.4B

+11.5%

Revenue grew 12% — the company sold more goods or services than the prior year.

Gross Profit

$4.7B

was $4.3B

+9.5%

Gross profit rose 10% — the spread between revenue and direct costs improved.

Risk Flags

0 high · 1 medium · 1 low
  • ◈ Medium

    Net income dropped 74% year-over-year — a significant compression in profitability.

  • ○ Low

    Stock is near its 52-week high (100.25) — the price reflects strong recent momentum, but entry risk is elevated at these levels.

Technical Signals

Daily closes · 1-year data

Edwards Lifesciences Corporation: common questions

Is Edwards Lifesciences Corporation profitable?

Yes. Edwards Lifesciences Corporation made a net profit of $1.1B in its latest fiscal year (fiscal 2025), a net margin of 17.7%.

Is Edwards Lifesciences Corporation's revenue growing?

Yes. Revenue grew 11.5% year on year, to $6.1B.

What is Edwards Lifesciences Corporation's P/E ratio?

Edwards Lifesciences Corporation trades at 59.2× its trailing twelve-month earnings. In other words, the share price is about 59 times the profit per share the company earned over the past year.

Does Edwards Lifesciences Corporation pay a dividend?

No dividend is currently expected from Edwards Lifesciences Corporation, according to the latest market data.

What are the main risks for Edwards Lifesciences Corporation?

Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Net income dropped 74% year-over-year — a significant compression in profitability.

Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — EW

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade EW

Links open broker research pages. Not an endorsement or recommendation.

Research Edwards Lifesciences Corporation

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.